Merck & Co Inc

• Merck shares rose due to positive oncology pipeline and Phase 3 trial data. • Strategic portfolio expansion and cardiovascular treatments alleviate patent expiration and revenue concerns. • Analysts maintain buy ratings with an average price target of $154.68.

• Merck will present Phase 3 trial results at the ESMO Congress 2026. • The company opened a new $500 million bioanalytical research facility in West Point. • Merck reported an annual revenue of $65.01B and net profit of $18.25B.

• Vaxcyte shares surged following positive Phase 3 clinical trial results for VAX-31. • Major Wall Street brokerages issued rating upgrades and raised their price targets. • The company completed a large capital raising initiative to fund operations.

• ImmunityBio shares surged amid upcoming executive conference participation and clinical data sentiment. • ANKTIVA commercialization and pipeline expansion drove investor interest and positive analyst upgrades. • Despite revenue growth, the company reported substantial net losses and heavy development expenditures.

• Moderna joined the Nasdaq-100 Index, creating mandatory passive fund buying pressure. • Phase 3 clinical trial success for its cancer vaccine bolstered investor sentiment. • Annual revenue reached $1.94 billion while net profit recorded a loss.

• Merck shares faced pressure due to revenue concentration concerns surrounding Keytruda. • Institutional position trimming and technical factors amplified the stock's downward momentum. • Analysts maintain an average price target of $151.95 for the company.